Prot# CSTI571 0110: A Phase II Study to Determine the Efficacy and Safety of STI571 in Patients with Chronic Myeloid Leukemia Who Are Refractory To Or Intolerant Of Interferon-Alpha

Project: Research project

Project Details

StatusFinished
Effective start/end date12/15/998/31/13

Funding

  • Novartis Pharmaceuticals Corporation (CSTI571 0110)